DHAKA, Feb 19, 2019 (BSS) – Country’s one of the leading pharmaceutical company BEXIMCO has procured eight products approved by the FDA of the Unite States (US) from the Sandoz.
This move would facilitate the BEXIMCO to export those products to US market by producing in its own plant in Bangladesh.
BEXIMCO Pharmaceuticals Limited (BPL) today made the announcement of signing of a definitive agreement with Sandoz, a division of Novartis, to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US, said a press release.
The acquisition expanded BPL’s US portfolio to 14 approved ANDAs. BPL’s current US portfolio comprises of six products approved by the US Food and Drug Administration (FDA). Four of these products are currently being exported to the US and two products are awaiting regulatory approval.
BPL Managing Director Nazmul Hassan, MP, said the acquisition of these ANDAs from Sandoz significantly strengthens BEXIMCO’S position in the United States.
“The acquisition is expected to provide a major boost to our export sales in the future and we look forward to continuing to build our presence in this important strategic market for Beximco Pharma,” he added.
In August 2016, Beximco Pharma became the first Bangladeshi pharmaceutical company to export medicine to the US market following its manufacturing site approval by the US FDA in June 2015.
Beximco Pharma, one of a leading exporter of pharmaceuticals, currently has a global footprint in more than 50 countries and has been accredited by the leading global regulatory authorities including the US FDA, AGES (EU), TGA (Australia), Health Canada, GCC (Gulf) and TFDA (Taiwan).